Were Lee Chan Henry’s BeOne Medicines share sales under a Rule 10b5-1 plan?

Yes. The filing states the ADS sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Lee Chan Henry on May 14, 2025. Such plans pre-schedule trades, providing a structured framework for selling shares over time.

What is the ADS to ordinary share ratio for BeOne Medicines (ONC)?

Each BeOne Medicines American Depositary Share represents 13 ordinary shares. This means ADS amounts reported in the filing correspond to a larger number of underlying ordinary shares, as explicitly stated in the footnotes to the insider transaction report.

BeOne SVP Henry sells 1,660 ADS after option exercise

BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry reported option exercises and share sales.

Accepted by SEC EDGAR 02/06/2026 - 04:57 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry reported option exercises and share sales. On 02/04/2026, Henry exercised three employee share options covering 6,526, 8,606 and 6,448 ordinary shares, which relate to American Depositary Shares (each ADS represents 13 ordinary shares).

On the same date, Henry sold 664 ADS at $348.79 and 996 ADS at $350.00 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, leaving no ADS directly held. Henry continues to directly hold 223,106 ordinary shares and significant remaining options that vest over multi-year schedules, subject to continued service and potential accelerated vesting on certain termination events.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 8 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 1,660 shs ($580K)

Approx. gross sale proceeds $580K

Approx. exercise cost $318K

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	6,526	$0.00	$0.00
Exercise	Share Option (Right to Buy)	8,606	$0.00	$0.00
Exercise	Share Option (Right to Buy)	6,448	$0.00	$0.00
Exercise	American Depositary Shares	502	$194.47	$98K
Exercise	American Depositary Shares	662	$213.32	$141K
Exercise	American Depositary Shares	496	$159.03	$79K
Sale	American Depositary Shares	664	$348.79	$232K
Sale	American Depositary Shares	996	$350.00	$349K
Holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 224,003 contracts (Direct); American Depositary Shares — 0 shares (Direct); Ordinary Shares — 223,106 shares (Direct)

Footnotes (6)

F1. Each American Depositary Share represents 13 Ordinary Shares.
F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
F3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and general counsel Lee Chan Henry exercised multiple share options into ordinary shares and corresponding ADS, then sold 1,660 American Depositary Shares on February 4, 2026, in two trades, as disclosed in a Form 4 insider transaction filing.

How many BeOne Medicines ADS did Lee Chan Henry sell, and at what prices?

Lee Chan Henry sold a total of 1,660 American Depositary Shares. The sales were 664 ADS at $348.79 and 996 ADS at $350.00, all executed on February 4, 2026, according to the reported non-derivative transactions in the insider filing.

What BeOne Medicines derivative securities did Lee Chan Henry exercise?

Lee Chan Henry exercised three “Share Option (Right to Buy)” grants on February 4, 2026, covering 6,526, 8,606 and 6,448 ordinary shares. These options had exercise prices represented in ordinary shares and relate to equity awards that vest over four-year schedules.

How many BeOne Medicines ordinary shares does Lee Chan Henry hold after these transactions?

Following the reported transactions, Lee Chan Henry directly beneficially owns 223,106 ordinary shares of BeOne Medicines. The filing also shows remaining option positions, with derivative securities beneficially owned totaling tens of thousands of underlying ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								223,106	D
American Depositary Shares⁽¹⁾	02/04/2026		M		502	A	$194.47	502	D
American Depositary Shares⁽¹⁾	02/04/2026		M		662	A	$213.32	1,164	D
American Depositary Shares⁽¹⁾	02/04/2026		M		496	A	$159.03	1,660	D
American Depositary Shares⁽¹⁾	02/04/2026		S⁽²⁾		664	D	$348.79	996	D
American Depositary Shares⁽¹⁾	02/04/2026		S⁽²⁾		996	D	$350	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$14.96⁽³⁾	02/04/2026		M			6,526	⁽⁴⁾	08/04/2032	Ordinary Shares	6,526	$0	23,920	D
Share Option (Right to Buy)	$16.41⁽³⁾	02/04/2026		M			8,606	⁽⁵⁾	06/14/2033	Ordinary Shares	8,606	$0	88,413	D
Share Option (Right to Buy)	$12.23⁽³⁾	02/04/2026		M			6,448	⁽⁶⁾	06/04/2034	Ordinary Shares	6,448	$0	111,670	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR